Alterity Therapeutics Ltd
ASX:ATH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alterity Therapeutics Ltd
Common Shares Outstanding
Alterity Therapeutics Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alterity Therapeutics Ltd
ASX:ATH
|
Common Shares Outstanding
AU$10.9B
|
CAGR 3-Years
65%
|
CAGR 5-Years
40%
|
CAGR 10-Years
35%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Common Shares Outstanding
$1.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
|
CSL Ltd
ASX:CSL
|
Common Shares Outstanding
$482.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Common Shares Outstanding
AU$180.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Common Shares Outstanding
AU$338.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Common Shares Outstanding
AU$597.2m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-12%
|
|
Alterity Therapeutics Ltd
Glance View
Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. The company is headquartered in Melbourne, Victoria and currently employs 11 full-time employees. The company went IPO on 2000-03-28. The firm focuses on developing disease modifying treatments for neurodegenerative conditions. The firm's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The firm also has a drug discovery platform generating chemical to intercede in disease processes.
See Also
What is Alterity Therapeutics Ltd's Common Shares Outstanding?
Common Shares Outstanding
10.9B
AUD
Based on the financial report for Dec 31, 2025, Alterity Therapeutics Ltd's Common Shares Outstanding amounts to 10.9B AUD.
What is Alterity Therapeutics Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
35%
Over the last year, the Common Shares Outstanding growth was 104%. The average annual Common Shares Outstanding growth rates for Alterity Therapeutics Ltd have been 65% over the past three years , 40% over the past five years , and 35% over the past ten years .
